Anyone who paid to take one of Theranos's blood tests in Arizona will be receiving a refund from the company, Arizona's attorney general said on Tuesday.In total, Theranos will pay the state $4.65 million to refund the tests, and will also pay $225,000 to cover civil penalties and attorneys' fees."Between 2013 and 2016, Theranos sold approximately 1.5 million blood tests to more than 175,000 Arizonans," the attorney general said in a news release. "Each customer will now be reimbursed the full amount the customer paid for testing regardless of whether the results were voided or corrected."It's the second settlement the embattled blood-testing company has made this week. On Monday, Theranos said that it had settled up withCenters for Medicare and Medicaid Services,the government agency responsible for regulating blood-testing labs.As part of the settlement, Theranos has to pay $30,000, and the company won't be able to own or operate a clinical lab within the next two years. In return, the CMS is no longer revoking Theranos's CLIA certification, which is needed to run a blood-testing lab.In January, The Wall Street Journal reported that Theranos had failed a CMS inspectionof its Arizona lab, just a few days before Theranos decided to shut down all of its clinical labs on October 5. A year earlier, Theranos's Northern California lab also failed a lab inspection.In October 2016,Theranospivoted to focus solely on developing its technologyinstead of simultaneously operating clinical laboratories. The end goal' Gettingits miniLab machine (which only requiresa small amount of blood to function) in places that have difficultiessending fullblood samples to a traditional, full-blown clinical lab operation.The technology debuted in August as part of Theranos' attempt to be what CEO Elizabeth Holmes called a "decentralized" lab, meaning the test could be processed without needing to be shipped backto a brick-and-mortar lab.Theranos'saga came into the spotlight in October 2015 after The Wall Street Journal published an investigation that questioned the accuracy of Theranos' blood test.The company still faces lawsuits from investors, patients, and its once partner Walgreens, which ended its relationship with Theranos in June 2016 and is accusing Theranos of breaching its contract. Theranos has said it will "respond vigorously to Walgreens' unfounded allegations."Financially, lawsuits like the one settled with Arizona can pack a punch. The Journal reported that Theranos had about $200 million in cash by the end of 2016, roughly a quarter of the money the company raised. The Journal also reported that Holmes now owes the company $25 million, and the companyis offering investorsadditional shares if they promise not to sue.SEE ALSO:A startup CEO who watched his 84-year-old mother struggle after leaving the hospital is on a mission to change healthcare from the 'inside out'DON'T MISS:A $12 billion startup you've probably never heard wants to cure baldness and smooth out your wrinklesJoin the conversation about this storyNOW WATCH: These are the only vitamins you should be taking ' and the ones you should skip
Click here to read full news..
